Claire V. Broome

Last updated
Claire Veronica Broome
Personal details
Born (1949-08-24) August 24, 1949 (age 74)
Tunbridge Wells, UK
SpouseJohn Head
Alma mater Harvard University
Profession Epidemiologist and physician

Claire Veronica Broome (born August 24, 1949) is an American epidemiologist, specializing in public health surveillance and vaccine evaluation, who has contributed to the development and effective utilization of key vaccines against pathogens causing pneumonia and meningitis. She joined the Centers for Disease Control and served with the CDC for 28 years, eventually holding the positions of deputy director, acting CDC director (1998), and senior advisor for integrated heath information systems. In 1995 she was promoted to assistant surgeon general in the US Public Health Service.

Contents

Early life

Claire Broome was born in Tunbridge Wells, England, on August 24, 1949, the daughter of Heather (Platt), a chemist and technical librarian, and Kenneth R. Broome, a civil engineer. The family emigrated to the United States in 1952. She earned a baccalaureate magna cum laude in biochemistry from Harvard University (Cambridge, MA) in 1970, and an MD from Harvard Medical School (Boston, MA) in 1975.

Career

Following a residency in internal medicine at the University of California, San Francisco (1975–77), she joined the Centers for Disease Control (CDC) as an Epidemic Intelligence Service (EIS) officer (1977–79) and served with the CDC for 28 years, eventually holding the positions of deputy director (1994–99), acting CDC director (1998), and senior advisor for integrated heath information systems (2000–06). In 1995 she was promoted to assistant surgeon general in the US Public Health Service.

During this period, Dr. Broome served as a chairperson for the World Health Organization (WHO) Steering Committee for Encapsulated Bacteria, which was responsible for funding and implementing a research portfolio on vaccines needed to prevent bacterial meningitis and pneumonia in developing countries (part of the WHO Programme for Vaccine Development, a predecessor of the CVI and GAVI).

From 1999 to 2006, she led the development and implementation of the National Electronic Disease Surveillance System (NEDSS), a project to transform public health surveillance in the US by electronic transmission of public health relevant clinical lab test results to state public health departments. These systems use the same standards which have been endorsed for clinical Electronic Health records; the majority of states in the country are now implementing one or more NEDSS functions. She also served as CDC's participant in national public private consortia to accelerate standards based Electronic Health Records.

Key scientific contributions

At the CDC, Broome contributed to the understanding of several diseases of high public interest including Legionnaires' Disease, [1] [2] [3] pneumococcal vaccine evaluation, [4] [5] meningococcal disease [6] and Toxic Shock Syndrome. [7] [8] Notable accomplishments included development of a new method for observational measurement of the effectiveness of the pneumoccal polysaccharide vaccine (the "indirect cohort" or "Broome" method), [9] which has been used since then to assess serotype specific effectiveness, duration of effectiveness, and effectiveness in groups with underlying disease; designed observational and field trials to evaluate vaccine performance, including sequential case control studies to define duration of meningococcal polysaccharide vaccine effectiveness in Burkina Faso; [10] a cluster randomized trial of Group B meningococcal vaccine efficacy in Cuba; and Haemophilus influenzae type b conjugate vaccine impact on pneumonia in the Gambia; creation of funded population based active surveillance sites for 5 invasive bacterial pathogens (the forerunner of domestic Emerging Infections Programs); and demonstration that epidemic and sporadic listeriosis was a food-borne disease. [11] [12]

Awards

Broome was elected to the Institute of Medicine in 1996 (now the National Academy of Medicine). Professional awards include the PHS Distinguished Service Award; the Surgeon General's Medallion; the Infectious Disease Society of America's Squibb Award for Excellence of Achievement in Infectious Diseases; the John Snow Award from the American Public Health Association, Epidemiology Section; 2020 Maxwell Finland Award for Scientific Achievement, National Foundation for Infectious Diseases; 2021 Schneerson-Robbins Prize, 15th Vaccine Congress; Charles Shepard Award 1986; Langmuir Award co-author 1981, 1983, 1988, 1989, 1993.

Related Research Articles

MeNZB was a vaccine against a specific strain of group B meningococcus, used to control an epidemic of meningococcal disease in New Zealand. Most people are able to carry the meningococcus bacteria safely with no ill effects. However, meningococcal disease can cause meningitis and sepsis, resulting in brain damage, failure of various organs, severe skin and soft-tissue damage, and death.

<span class="mw-page-title-main">Conjugate vaccine</span> Type of vaccine

A conjugate vaccine is a type of subunit vaccine which combines a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

<span class="mw-page-title-main">Pneumococcal polysaccharide vaccine</span> Pneumonia vaccine

Pneumococcal polysaccharide vaccine, sold under the brand name Pneumovax 23, is a pneumococcal vaccine that is used for the prevention of pneumococcal disease caused by the 23 serotypes of Streptococcus pneumoniae contained in the vaccine as capsular polysaccharides. It is given by intramuscular or subcutaneous injection.

<i>Neisseria meningitidis</i> Species of bacterium that can cause meningitis

Neisseria meningitidis, often referred to as the meningococcus, is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease such as meningococcemia, a life-threatening sepsis. The bacterium is referred to as a coccus because it is round, and more specifically a diplococcus because of its tendency to form pairs.

<span class="mw-page-title-main">Meningococcal disease</span> Medical condition

Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis. It has a high mortality rate if untreated but is vaccine-preventable. While best known as a cause of meningitis, it can also result in sepsis, which is an even more damaging and dangerous condition. Meningitis and meningococcemia are major causes of illness, death, and disability in both developed and under-developed countries.

<span class="mw-page-title-main">Pneumococcal conjugate vaccine</span> Vaccine against Strep pneumoniae

Pneumococcal conjugate vaccine is a pneumococcal vaccine and a conjugate vaccine used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children.

Robert Austrian was an American infectious diseases physician and, along with Maxwell Finland, one of the two most important researchers into the biology of Streptococcus pneumoniae in the 20th century.

Allen Caruthers Steere is an American rheumatologist. He is a professor of rheumatology at Harvard University and previously at Tufts University and Yale University. Steere and his mentor, Stephen Malawista of Yale University, are credited with discovering and naming Lyme disease, and he has published almost 300 scholarly articles on Lyme disease during his more than 40 years of studies of this infection. At a ceremony in Hartford, Connecticut in 1998, Governor John G. Rowland declared September 24 to be "Allen C. Steere Day."

<span class="mw-page-title-main">Hib vaccine</span> Haemophilus influenzae type B vaccine

The Haemophilus influenzae type B vaccine, also known as Hib vaccine, is a vaccine used to prevent Haemophilus influenzae type b (Hib) infection. In countries that include it as a routine vaccine, rates of severe Hib infections have decreased more than 90%. It has therefore resulted in a decrease in the rate of meningitis, pneumonia, and epiglottitis.

<span class="mw-page-title-main">JN-International Medical Corporation</span> Pharmaceutical company in Nebraska, United States

JN-International Medical Corporation (JNIMC) is a U.S.-based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation was founded in 1998 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska.

NmVac4-A/C/Y/W-135 is the commercial name of the polysaccharide vaccine against the bacterium that causes meningococcal meningitis. The product, by JN-International Medical Corporation, is designed and formulated to be used in developing countries for protecting populations during meningitis disease epidemics.

<span class="mw-page-title-main">Meningitis</span> Inflammation of the membranes around the brain and spinal cord

Meningitis is acute or chronic inflammation of the protective membranes covering the brain and spinal cord, collectively called the meninges. The most common symptoms are fever, intense headache, vomiting and neck stiffness and occasionally photophobia.

Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

<span class="mw-page-title-main">Anne Schuchat</span> American physician (born 1960)

Anne Schuchat is an American medical doctor. She is a former rear admiral and assistant surgeon general in the United States Public Health Service Commissioned Corps. She also served as the principal deputy director of the Centers for Disease Control and Prevention (CDC). In May 2021, Schuchat stepped down from her post.

<span class="mw-page-title-main">African meningitis belt</span> Region of Africa with high rate of incidence of meningitis

The African meningitis belt is a region in sub-Saharan Africa where the rate of incidence of meningitis is very high. It extends from Senegal to Ethiopia, and the primary cause of meningitis in the belt is Neisseria meningitidis.

MenAfriVac is a vaccine developed for use in sub-Saharan Africa for children and adults between 9 months and 29 years of age against meningococcal bacterium Neisseria meningitidis group A. The vaccine costs less than US$0.50 per dose.

<span class="mw-page-title-main">Meningitis Vaccine Project</span>

The Meningitis Vaccine Project is an effort to eliminate the meningitis epidemic in Sub-Saharan Africa by developing a new meningococcal vaccine. The meningitis problem in that area is caused by a strain of meningitis called "meningitis A", which is present only in the African meningitis belt. In June 2010 various sources announced that they had developed MenAfriVac, which is an inexpensive, safe, and highly effective vaccine which is likely to stop the epidemic as quickly as anyone had ever hoped that it would.

James Gregory Zimmerly was an American emergency department physician and chief of legal medicine at the Armed Forces Institute of Pathology. He co–discovered a vaccine for meningitis in 1970. He died in 2002 following a brain aneurysm and is buried at Arlington National Cemetery, in Arlington, Virginia.

Daniel Michael Musher is an American physician, scientist, and medical educator working in the field of infectious diseases, who has coauthored more than 600 publications. Musher is a Distinguished Service Professor of Medicine and Professor of Molecular Virology and Microbiology at the Baylor College of Medicine in Houston, Texas.

Trudy Virginia Noller Murphy is an American pediatric infectious diseases physician, public health epidemiologist and vaccinologist. During the 1980s and 1990s, she conducted research at Southwestern Medical School in Dallas, Texas on three bacterial pathogens: Haemophilus influenzae type b (Hib), Streptococcus pneumoniae (pneumococcus), and methicillin-resistant Staphylococcus aureus (MRSA). Murphy's studies advanced understanding of how these organisms spread within communities, particularly among children attending day care centers. Her seminal work on Hib vaccines elucidated the effects of introduction of new Hib vaccines on both bacterial carriage and control of invasive Hib disease. Murphy subsequently joined the National Immunization Program at the Centers for Disease Control and Prevention (CDC). where she led multi-disciplinary teams in the Divisions of Epidemiology and Surveillance and The Viral Hepatitis Division. Among her most influential work at CDC was on Rotashield™, which was a newly licensed vaccine designed to prevent severe diarrheal disease caused by rotavirus. Murphy and her colleagues uncovered that the vaccine increased the risk of acute bowel obstruction (intussusception). This finding prompted suspension of the national recommendation to vaccinate children with Rotashield, and led the manufacturer to withdraw the vaccine from the market. For this work Murphy received the United States Department of Health and Human Services Secretary's Award for Distinguished Service in 2000, and the publication describing this work was recognized in 2002 by the Charles C. Shepard Science Award from the Centers for Disease Control and Prevention.

References

  1. ↑ Broome CV, Cherry WB, Winn WC Jr, MacPherson BR: Rapid diagnosis of Legionnaires' disease by direct immunofluorescent staining. Ann Intern Med 1979;90:1 4.
  2. ↑ Broome CV, Goings SAJ, Thacker SB, Vogt RL, Beaty HN, Fraser DW, the Field Investigation Team: the Vermont epidemic of Legionnaires' disease. Ann Intern Med 1979;90:573 576.
  3. ↑ England AC III, Fraser DW, Plikaytis BD, Tsai TF, Storch G, Broome CV. Sporadic legionellosis in the United States: the first thousand cases. Ann Intern Med 1981;94:164 170.
  4. ↑ Broome CV, Facklam RR, Austrian R, Allen JR, Fraser DW. Epidemiology of pneumococcal serotypes in the United States, 1978 1979. J Infect Dis 1980;141:119 123.
  5. ↑ Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980;303:549 552.
  6. ↑ Broome CV, Rugh MA, Yada AA, Giat L, Giat H, Zeltner JM, Sanborn WR, Fraser DW. Epidemic group C meningococcal meningitis in Upper Volta, 1979. Bull World Health Organ 1983;61:325 330.
  7. ↑ Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, Anderson RL, Hill DK, Broome CV, Band JD, Fraser DW. Toxic shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 1980;303:1436 1442
  8. ↑ Reingold AL, Hargrett NT, Shands KN, Dan BB, Schmid GP, Strickland BY, Broome CV. Toxic shock surveillance in the United States, 1980 81. Ann Internal Med 1982;96:875 880.
  9. ↑ Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986;104:1 6.
  10. ↑ Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum C, Jones EE, Phillips C, Tiendrebeogo H, Yada A. Age specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. The Lancet 1985;ii:114 118.
  11. ↑ Schlech WF, Lavigne PM, Bortolussi RA, Allen AC, Haldane EV, Wort JA, Hightower AW, King SH, Nicholls ES, Broome CV. Epidemic listeriosis: Evidence for transmission by food. N Engl J Med 1983; 308:203 206.
  12. ↑ Schuchat A1, Deaver KA, Wenger JD, Plikaytis BD, Mascola L, Pinner RW, Reingold AL, Broome CV. Role of foods in sporadic listeriosis. I. Case-control study of dietary risk factors. The Listeria Study Group.JAMA 1992;267:2041-5.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.